Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF(V600E) Mutation

BACKGROUND: Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kim, Kevin B., Cabanillas, Maria E., Lazar, Alexander J., Williams, Michelle D., Sanders, Deborah L., Ilagan, Joseph L., Nolop, Keith, Lee, Richard J., Sherman, Steven I.
Formato: Artigo
Idioma:Inglês
Publicado: Mary Ann Liebert, Inc. 2013
Assuntos:
Thyroid Cancer and Nodules
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3967415/
https://ncbi.nlm.nih.gov/pubmed/23489023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2013.0057
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares